Merck & Co.’s Keytruda Leads Non-Small Lung Cancer (NSCLC) Therapeutics Market, Says GlobalData in Its Report Now Available at MarketPublishers.com25 Jan 2017 • by Natalie Aster
LONDON – At present, lung cancer is recognised as the most common cause of death from cancer globally. Meantime, nearly 85% of all lung cancer cases are non-small cell lung cancer (NSCLC) sub-type.
Unfortunately, NSCLC patients are more often diagnosed in the later stages of the disease, with poor prognosis. Historically, therapeutic options for advanced-stage of NSCLC have been led by chemotherapy. But, the introduction of targeted therapies like Iressa (gefitinib) in the year 2003, then Tarceva (erlotinib) in the year 2004 and Xalkori (crizotinib) in the year 2011, has changed the trajectory of the treatment landscape towards personalised medicine.
The combined value of the 5EU markets for NSCLC stood at around USD 1.53 billion. Growth in these markets is encouraged by the constantly rising usage of immunotherapies across histologies and lines of NSCLC therapy.
The usage of PD-1 checkpoint inhibitors in first-line NSCLC therapy is anticipated to enjoy the highest sales from conventional chemotherapies, which are typically used in the first line.
Today, Merck & Co.’s Keytruda is the leader in the first-line setting, as it is already approved as a monotherapy for ≥50% PD-L1+ patients, furthermore, it is showing benefits in combination with chemotherapy regardless of PD-L1 expression.
The topical GlobalData’s report titled “Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025” is a reliable source of updated information on the NSCLC therapeutics market landscape, key approved treatment options and statistics on top drug sales. This publication includes details on NSCLC symptoms, epidemiology, diagnosis, etiology, pathology and treatment options; offers detailed analyses of 5 major EU country-wide markets for NSCLC therapeutics, includes SWOT analysis, discusses key challenges and opportunities and also presents access to valuable all-round forecasts for the market up till 2025.
For many other research studies by this publisher, follow to the GlobalData page at MarketPublishers.com.